Safety of conjugated linoleic acid (CLA)-rich oil (Clarinol®)


Conjugated Linoleic Acid, insulin sensitivity, blood lipids, novel food ingredient, Lipid Nutrition
First published in the EFSA Journal
21 May 2010
30 April 2010
Last Updated
26 May 2010. This version replaces the previous one/s.
Scientific Opinion

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to carry out the additional assessment for Clarinol®, a conjugated linoleic acid (CLA)-rich oil, as a food ingredient in the context of Regulation (EC) No. 258/97. Clarinol® consists of approximately 80 % of the two CLA isomers c9,t11:t10,c12 (1:1). Clarinol® is intended by the applicant as an ingredient in beverages, cereal products, dietary supplements, milk products and dry weight beverages for adult consumers. The applicant suggests a daily intake of 3 g CLA, corresponding to approximately 3.75 g Clarinol®. The available data from non-human studies do not indicate a risk for genotoxicity, reproductive toxicity, carcinogenicity or allergenicity. The extent of the effects of CLA on insulin resistance and on markers of cardiovascular risk appears to be species-dependent. Therefore the focus of this safety assessment relies mainly on the large number of available human studies. Based on the assessment of these studies, the Panel considers that CLA consumption does not appear to have adverse effects on insulin sensitivity, blood glucose control or liver function for up to six months, and that observed effects on blood lipids are unlikely to have an impact on cardiovascular risk. Long-term effects of CLA intake on insulin sensitivity and the arterial wall have not been adequately addressed in humans. The Panel concludes that the safety of Clarinol® has been established for the proposed uses at intakes of 3.75 g per day (corresponding to 3 g CLA), for up to six months. The safety of CLA consumption for periods longer than six months has not been established under the proposed conditions of use. The safety of CLA consumption by type-2 diabetic subjects has not been established.

Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
nda [at]
EFSA Journal 2010; 8(5):1601 [41 pp.].
Question Number
On request from
European Commission
Print on demand
Number of Pages